Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

(2012) Naomi Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Canakinumab in gout

(2012) Naomi Schlesinger   EXPERT OPINION ON BIOLOGICAL THERAPY

Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials

(2011) W. J. TAYLOR et al.   JOURNAL OF RHEUMATOLOGY

Minimally important differences of the gout impact scale in a randomized controlled trial

(2011) D. Khanna et al.   RHEUMATOLOGY

Clinical manifestations of hyperuricemia and gout

(2009) B. F. MANDELL   CLEVELAND CLINIC JOURNAL OF MEDICINE

Gout – what are the treatment options?

(2009) Naomi Schlesinger et al.   EXPERT OPINION ON PHARMACOTHERAPY

Quality of Life and Disability in Patients with Treatment-Failure Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life

(2008) Jan D. Hirsch et al.   JOURNAL OF RHEUMATOLOGY